ArticleCureus2026
First Case of Deficiency of Adenosine Deaminase 2 (DADA2) in Oman With a Novel Mutation: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deficiency of adenosine deaminase 2 (DADA2) is a rare autosomal recessive disorder that results from biallelic loss-of-function mutations in the ADA2 gene. It is characterized by a spectrum of clinical features, predominantly vasculitis, autoinflammation, dysregulated immune function, and hematologic abnormalities, making it a challenging condition to diagnose. This case report presents the first documented case of DADA2 in Oman, highlighting a novel mutation in the ADA2 gene. It provides insights into the diagnostic process, therapeutic strategies, systemic evaluations, and family-focused management, contributing to the growing understanding of this rare disorder. This is a case of an 18-month-old male toddler who presented with persistent bi-cytopenia and a history of febrile seizures. Genetic testing revealed a novel homozygous pathogenic variant in the ADA2 gene. The patient was managed with infliximab infusions and regular follow-up. This report enhances the understanding of DADA2. The identification of a novel mutation in this case further highlights the growing insight into the pathogenesis of DADA2 and its clinical implications. Effective management requires genetic testing, systemic evaluation, and targeted therapy. Genetic counseling and family screening are crucial for early intervention and disease prevention. Further research is needed to improve diagnostics, treatments, and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.